# US 2026/0076991 A1 · Hyaluronic Acid Nanoparticles Comprising NADPH Oxidases Inhibitors and Uses in Treating Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076991 A1
- Document ID: US20260076991A1
- Status: Published application
- Kind: A1
- Application number: 19/258,752
- Filed: 2025-07-02
- Published: 2026-03-19
- Earliest claimed: 2019-04-01
- Assignees: Emory University
- Applicants: Emory University
- Inventors: Lily Yang; Lei Zhu
- Web page: https://patentgrep.com/patent/US20260076991A1

## CPC

- A61K 31/728: Hyaluronic acid
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61K 47/6939: {the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin}
- A61P 35/00: Antineoplastic agents
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid.

## Claims

### Claim 1

A nanoparticle comprising 50-cholanic acid conjugated to hyaluronic acid and 2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1,2-dihydro-3H-pyrazolo[4,3-c]pyridine-3,6(5H)-dione or salt thereof.

### Claim 2 (depends on 1)

The nanoparticle of claim 1 which is 202 nm plus or minus 16 nm in diameter.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising the nanoparticle of claim 1 and pharmaceutically acceptable excipient.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3 in the form of a gel, tablet, or capsule.

### Claim 5 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is glucose, sucrose, mannitol, lactose, or sorbitol.

### Claim 6 (depends on 3)

The pharmaceutical composition of claim 3 is in the form of a pH buffered solution.

### Claim 7 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is sodium citrate.

### Claim 8 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is sodium carbonate or calcium carbonate.

### Claim 9 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is alginate.

### Claim 10 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is gelatin.

### Claim 11 (depends on 3)

The pharmaceutical composition of claim 3 wherein the pharmaceutically acceptable excipient is polyvinylpyrrolidone.

### Claim 12 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is dicalcium phosphate.

### Claim 13 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is glycerol or glycerol monostearate.

### Claim 14 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is cetyl alcohol.

### Claim 15 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is polyethylene glycol.

### Claim 16 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is sodium lauryl sulfate.

### Claim 17 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is dextrin.

### Claim 18 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is cellulose, methylcellulose, carboxymethylcellulose, ethylcellulose, or hydroxypropylcellulose.

### Claim 19 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable excipient is calcium stearate or magnesium stearate.
